Aldeyra Therapeutics, Inc. received minutes from a June 10, 2026, Type A meeting with the FDA concerning the potential resubmission of its New Drug Application (NDA) for reproxalap to treat dry eye disease. Following the receipt of these minutes, the company requested clarification from the FDA on July 15, 2026. Aldeyra also plans to request a Type D meeting with the FDA, which is anticipated to occur by the end of the third quarter of 2026. Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated diseases.